Alnylam Pharmaceuticals (ALNY) Convertible Debt (2022 - 2026)

Alnylam Pharmaceuticals (ALNY) has 5 years of Convertible Debt data on file, last reported at $1.0 billion in Q2 2026.

• Quarterly Convertible Debt fell 1.51% year-over-year to $1.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.0 billion (down 1.51% YoY) and the FY2025 annual result came in at $1.0 billion, down 1.64% from the prior year.
• Convertible Debt was little changed at $1.0 billion in Q2 2026, from $1.0 billion in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $1.0 billion in Q3 2025 to a low of $1.0 billion in Q4 2025.
• A 5-year average of $1.0 billion and a median of $1.0 billion in 2023 frame the typical range for Convertible Debt.
• The widest YoY moves for Convertible Debt: up 1.62% in 2025, down 1.64% in 2025.
• Tracing ALNY's Convertible Debt over 5 years: stood at $1.0 billion in 2022, then increased by 0.38% to $1.0 billion in 2023, then rose by 0.38% to $1.0 billion in 2024, then retreated by 1.64% to $1.0 billion in 2025, then rose by 0.32% to $1.0 billion in 2026.
• The last three Convertible Debt figures came in at $1.0 billion (Q2 2026), $1.0 billion (Q1 2026), and $1.0 billion (Q4 2025), per Business Quant data.